Latest
19:53
【Biocytogen-B (02315): Enters Option-Rights Agreement with Acepodia to Advance Bispecific ADC Programs】Biocytogen (2315) announced on January 12 an option and license agreement with Acepodia, granting global exclusive options on two BsADC projects to accelerate bispecific antibody-dual drug conjugate (BsAD2C) development. Biocytogen will receive upfront and subsequent milestone payments plus royalties. The collaboration combines Biocytogen's RenLite® platform with Acepodia's AD2C technology, building upon a joint development partnership initiated earlier this year. Acepodia and its ultimate beneficial owners are independent of Biocytogen and its connected persons, and the transaction does not constitute a connected transaction. The company cautions shareholders and potential investors to exercise prudence when trading its shares.
Tag:
BIOCYTOGEN-B02315.HK